An interventional study of Unified Protocol in Emotional Disorders, Anxiety and Depression - Major Depressive Disorder, sponsored by University of Bergen. Recruiting at 1 site in Norway. Open to participants aged 18 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-08-19.
Sponsored by University of Bergen · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 92 studies in Anxiety Disorders with a site in Norway — 22 open to participants now, 32 under way, none of them phase 3. Anxiety Disorders · Norway.
Among the 92 studies in Anxiety Disorders with a site in Norway, this one is the 38th largest by planned enrollment of the 72 interventional ones that give a count, is one of 9 that started in 2025, is one of 63 with no phase, reaches primary completion later than 27 of the 31 other live ones, and was the 81st registered.
7,249 studies on the registry are indexed under Anxiety Disorders; 1,691 are open to participants now.
Browse Anxiety Disorders studies →22 of the 92 studies in Anxiety Disorders with a site in Norway are open now. Recruiting first, the newest first:
Sorlandet Hospital HF · Sites in Norway
Ages 10–16
University of Oslo · Sites in Norway
Ages 16–19
Sorlandet Hospital HF · Sites in Norway
Ages 18+
Sorlandet Hospital HF · Sites in Norway
Ages 16–25
Helse Stavanger HF · Sites in Norway
Ages 13–18
A study can be open while its sites in Norway have not opened yet or have stopped. Only those recruiting at a site in Norway →
Of the 947 Anxiety Disorders studies recruiting now, 423 (45%) set no upper age limit and 455 (48%) stop at 75 or younger; 233 take children under 18; 319 take healthy volunteers.
This study: 18 Years to 40 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
92 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 4 · Phase 3 3 · Phase 4 1
First in 1993; this study’s year is marked. 9 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 140 is above the median of 80 across 6,103 interventional studies indexed under Anxiety Disorders.
Median enrollment 155 across the 72 interventional studies, 660 across the 20 observational. Of the 51 that completed or were terminated, 1 (2%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 92 have an industry lead sponsor. The 10 most frequent:
University of Bergen is the lead sponsor of 143 studies on the registry; 19 are open to participants now.
University of Bergen has 6 studies filed under Anxiety Disorders — fewer than ten, so there is no comparison to draw.
7 of the studies in Anxiety Disorders with a site in Norway that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07864324University Hospital of North NorwayHigh-Intensity Interval Training and Mental Health in Psychiatric Inpatients | 2026-12-15 |
| NCT06777693NKS Olaviken Gerontopsychiatric HospitalThe Unified Protocol for Transdiagnostic Treatment of Emotional Disorders in Older Adults: a Feasibility Study | 2026-12-24 |
| NCT07000799University of OsloA Study of School Absenteeism and Student Well-being in Elementary Schools | 2026-12-31 |
| NCT07145307Helse Stavanger HFPersonalized Digital Treatment for Adolescent Anxiety: A Feasibility Trial | 2027-04 |
| NCT06568419Solli Distriktspsykiatriske SentereBehandling - Health and Work for Patients in Specialist Mental Health Care | 2027-04 |
Add all 7 to your calendar (.ics) → With an account.
Among the 92 studies in Anxiety Disorders with a site in Norway, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This clinical trial aims to evaluate the effectiveness and underlying processes of change of the Unified Protocol (UP) for treating emotional disorders in a university outpatient clinic. The study will involve 140 patients receiving UP treatment in a group format, delivered either by experienced or novice therapists, along with a non-clinical control group of 45 participants. Participants will self-refer on the basis of advertisement about the study through flyers, posters, project website, social media or local news media. Outcomes will be assessed through self-report measures of well-being, symptoms, emotion regulation, and the non-specific factors of treatment credibility and therapeutic alliance. Additionally, psychophysiological measures of heart rate variability and interoception will be used to explore processes influencing treatment response. Qualitative interviews will complement the quantitative data by capturing participants' perspectives on the treatment and experiences of what contributed to change.
Background Anxiety and depression are the most common mental disorders, incurring vast personal and societal costs. While effective evidence-based treatments exist, healthcare systems struggle to meet the growing demand for services. A key challenge in delivering care is that most treatments are diagnosis specific. This complicates training and implementation due to clinicians having to learn multiple treatment manuals. In addition, these single-disorder treatments may also often have poor applicability to the complex symptoms and patterns of comorbidity typically seen in real-world clinical settings. As a response to these challenges, several transdiagnostic treatment protocols have been developed to target psychological processes underlying different diagnoses. One such model is the "Unified Protocol for Transdiagnostic Treatment of Emotional Disorders" (UP) developed by David Barlow and colleagues. UP addresses the functional processes that maintain emotional disorders, such as negative reactions to emotions and avoidance behaviors.
The Unified Protocol (UP) has shown non-inferiority to diagnosis-specific CBT and superiority to treatment as usual in both individual and group formats. Meta-analyses confirm its effectiveness for comorbid emotional disorders and suggest potential for cost-effective, scalable implementation.
Knowledge gaps
Study objectives This study aims to explore outcomes, processes of change, and user experiences of UP group treatment for patients with emotional disorders in a naturalistic clinical sample in a Norwegian setting. Additionally, it will compare the clinical sample to a healthy control group to better understand how transdiagnostic characteristics serve as vulnerability or resilience factors in the development of emotional disorders. Lastly, the study examines whether novice therapists can be trained to deliver the treatment with high levels of fidelity based on ratings of adherence and competence.
Main aims and research questions i. Assessing treatment effectiveness: To determine whether UP group treatment leads to improvements in key clinical outcomes, identify factors that influence these outcomes, and assess any negative treatment effects.
Research questions:
ii. Examining processes of change: To investigate the role of emotion regulation, interoception, and UP skill use as predictors and mediators of treatment outcomes, using both self-report and objective measures.
Research questions:
iii. Understanding patients' experience of UP: To explore patients' experience of UP treatment through in-depth qualitative interviews.
Research questions:
iv.) Understanding transdiagnostic factors in emotional vulnerability and resilience: To explore whether individuals with emotional disorders differ cross-sectionally from healthy controls.
Research question:
- Do patients with emotional disorders differ significantly from healthy controls on measures of emotion regulation, acceptance, cognitive flexibility, and psychophysiological markers (interoception, heart rate variability)?
v.) Examining UP group therapy delivered by novices: To assess whether novice therapists can be trained to deliver UP with high fidelity.
Research question:
- Can novice therapists (i.e., graduate students in clinical psychology under supervision) be trained to high levels of fidelity in delivering the UP group treatment?
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
The Unified Protocol (UP) is a time-limited modular treatment addressing core emotion regulation difficulties in patients with emotional disorders. There will be 8-10 patients and two or three therapists in the group. Treatment consists of one individual session of diagnostic assessment, and one or two individual preparation sessions (case formulation and goal setting), and 12 weekly 2 ½ hour group treatment sessions.
Behavioral: Unified Protocol
The Unified Protocol is a transdiagnostic intervention for emotional disorders here delivered in a group format
WHO-5: Wellbeing index
The WHO-5 is a self-report measure of positive mental health. It consists of five items that are rated on a 6-point scale from 'All of the time' to 'At no time'. High scores indicate a more positive rating of wellbeing
Time frame: From enrollment to follow-up at 6 months
Work and Social Adjustment Scale
The WSAS is a five-item scale that addresses impairments in work/study, home, social life, private leisure activities, and interpersonal relations. Each item is self-rated on a nine-point Likert scale that ranges from "Not at all" (0) to "Severely impaired" (8).
Time frame: From enrollment to follow-up at 6 months
Patient Health Questionnaire (PHQ-9)
The PHQ-9 is a nine-item scale measuring depression severity. Each item is self-rated on a four-point Likert scale that ranges from "Not at all" (0) to "Nearly every day" (3).
Time frame: From enrollment to follow-up at 6 months
Generalized Anxiety Disorder Scale (GAD-7)
The GAD-7 is a seven-item scale measuring anxiety severity. Each items is self-rated on a four point Likert scale that ranges from "Not at all" (0) to "Nearly every day" (3).
Time frame: From enrollment to follow-up at 6 months
Multidimensional Emotional Disorders Inventory (MEDI)
The MEDI is a 49-item scale measuring nine transdiagnostic factors involved in emotional disorders. Each item is self-rated on a nine point Likert scale that ranges from 0 (Not at all characteristic of me) to 8 (Totally characteristic of me). The dimensions measured are Neurotic temperament, positive temperament, depressive mood, autonomic arousal, somatic anxiety, intrusive thoughts, traumatic re-experiencing and avoidance.
Time frame: From enrollment to follow-up at 6 months
Level of Personality Functioning Scale Brief Form (LPFS-BF)
The LPFS-BF is a 12-item scale measuring the level of personality functioning based on the Criterion "A" of the alternative model for personality disorders in the DSM-5; Identity, self-direction, empathy and intimacy. Each item is self-rated on a 4-point Likert scale that ranges from 0 (Little or no impairment) to 3 (Severe impairment).
Time frame: From enrollment to follow-up at 6 months
Difficulty in Emotion Regulation Scale (DERS-16)
The DERS is a 16-item scale measuring individuals' typical levels of difficulties in emotion regulation. Each item is self-rated on a 5-point Likert scale that ranges from 1 (Almost never) to 5 (Almost always).
Time frame: From enrollment to follow-up at 6 months
Acceptance and Action Questionnaire- version 2 (AAQ-II)
The AAQ-II is a 7-item scale measuring experiential avoidance and psychological inflexibility. Each item is self-rated on a 7-point Likert scale that ranges from 1 (Never right) to 5 (Always right). The total score ranges between 0-49. Higher scores indicate less psychological flexibility and more experiential avoidance.
Time frame: From enrollment to follow-up at 6 months
Five Facet Mindfulness Questionnaire (FFMQ)
The FFMQ is a 15-item scale measuring mindfulness with regard to thoughts, experiences, and actions in daily life. Each item is self-rated on a 5-point Likert scale that ranges from 1 (Never or rarely true) to 5 (Very often or always true).
Time frame: From enrollment to follow-up at 6 months
Unified Protocol Cognitive Skills Questionnaire (UP-CSQ)
The UP-CSQ is a 7-item scale measuring the cognitive skills taught in the UP. Each item is self-rated on a 5-point Likert scale that ranges from 1 (Never) to 5 (Always or when needed)
Time frame: From enrollment to follow-up at 6 months
Multidimensional Assessment of Interoceptive Awareness-2 (MAIA)
The MAIA is a 37-item scale measuring interoceptive awareness. Each item is self-rated on a 6-point Likert scale that ranges from 0 (Never) to 5 (Always).
Time frame: From enrollment to follow-up at 6 months
Overall Anxiety Severity and Impairment Scale (OASIS)
The OASIS is a 5-item scale measuring the frequency and severity of anxiety, avoidance, work/school/home interference, and social interference due to anxiety. Each item is self-rated on a 5-point Likert scale that ranges from 0 (None, never) to 4 (Extreme, constant). The OASIS is used as an in-session UP measures to examine processes of change
Time frame: At each treatment session through the 12 weeks of treatment
Overall Depression Severity and Impairment Scale (ODSIS)
The ODSIS is a 5-item scale measuring the frequency and severity of depression symptoms, avoidance, work/school/home interference, and social interference due to depression. Each item is self-rated on a 5-point Likert scale that ranges from 0 (None/never) to 4 (Extreme/constant). The ODSIS is used as an in-session UP measures to examine processes of change
Time frame: At each treatment session through the 12 weeks of treatment
Unified Protocol Skill Use Scale (UPSUS)
The UPSUS is a 7-item scale measuring the frequency with which individuals use UP-skills in distressing situations. Each item is self-rated on a 6-point Likert scale that ranges from 0 (Not at all) to 5 (Nearly all the time). Each item was written to describe core skills taught in each of the five core UP-modules. The UPSUS is used as an in-session UP measure to examine processes of change
Time frame: At each treatment session through the 12 weeks of treatment
Dimension of Skillfulness and Use Scale (DSUS)
The DSUS is a 4-item scale measuring the understanding of UP skills learned in the prior session, frequency of skill use, quality of skill use, and effectiveness and skill use. Each item is self-rated on a 5-point Likert scale that ranges from 0 (Not at all) to 4 (Extremely well/every day). The DSUS is used as an in-session UP measures to examine processes of change
Time frame: At each treatment session through the 12 weeks of treatment
Client Satisfaction Questionnaire (CSQ-8)
The CSQ-8 is an 8-item scale measuring clients' satisfaction with treatment. Each item is scored on a 4-point Likert scale that ranges from 0 to 3.
Time frame: At final treatment session (week 12)
The Negative Effects Questionnaire (NEQ)
The NEQ is a 32-item scale measuring adverse or unwanted events during treatment. Each item is designed to assess adverse effects related to psychological treatments. Items are scored on a five-point Likert scale (0-4) and differentiates between treatment-related negative effects and those from external factors.
Time frame: At final treatment session (week 12)
The Heartbeat Counting Task (HBC)
The HBC task evaluates three dimensions of interoception: 1) Interoceptive accuracy in the form of ratio of detected to actual heartbeats, 2) Interoceptive sensibility in the form of self-reported interoception through interviews and questionnaires, and 3) Interoceptive awareness in the form of metacognitive awareness of accuracy, measured by the correlation between confidence and actual performance using receiver operating characteristics (ROC) curve analysis.
Time frame: From enrollment to follow-up at 6 months
Heart Rate Variability (HRV) via a 24-hour ECG Monitoring.
24-hour ECG data will be collected using BioPoint sensors from SiFi Labs, which are wearable, small and designed for continuous monitoring. The sensor is placed below the sternum. The data are not intended for clinical evaluation of heart function but suitable for investigating potential changes in HRV before and after psychotherapy in addition to possible differences in HRV in groups of patients with emotional disorders compared to healthy controls.
Time frame: From enrollment to follow-up at 6 months
Credibility Rating Scale
The version of the Credibility Rating Scale used in this study is a 5-item adapted version of the original Credibility Rating Scale developed by Devilly \& Borkovec.
Time frame: This scale will be administered only at pre-treatment as a possible predictor of change.
Group Session Rating Scale (GSRS)
The GSRS is a 4-item scale measuring each participant's experience of alliance in the UP group therapy. Each item is scored on a visual analog scale, covering the patient's experience of the quality of the relations to both the therapist and the other patients in the group, the personal relevance of the goals and themes of the group session, the fit of the approach utilized in the treatment, and the general experience of being part of the group.
Time frame: At each treatment session through the 12 weeks of treatment
Plan to share: No
No publications or documents are linked to this record.
Started May 2025 (actual). Primary completion is estimated for Dec 2028, 43 months after the start.
Of 3,871 non-industry interventional studies with no phase under Anxiety Disorders, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 28. This study's planned 43 months is above that.
Counting every sponsor, half of 3,976 studies reached it within 12 months; a quarter within 5 and three quarters within 28.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.